Diabetes Case Reports

AI-Guided (GenAISâ?¢) dietary supplement prescriptions in type 2 diabetes and hypercholesterolemia management

7^th Annual Meeting on Diabetes and Endocrinology

November 18, 2024 | Webinar

Evgeny Pokushalov

Triangel Scientific, USA

Scientific Tracks Abstracts: J Psychiatry

Abstract:

Introduction: Artificial Intelligence (AI) is revolutionizing personalized healthcare, particularly in the management of chronic conditions like Type 2 diabetes (T2D) and hypercholesterolemia. This presentation will discuss two pioneering randomized trials evaluating the efficacy of AI-guided dietary supplement (DS) regimens using the GenAISâ?¢ system in optimizing glycemic control and lipid metabolism, compared to traditional physician guided approaches. Study 1: AI-Guided Dietary Supplements for Glycemic Control in T2D Objective: Evaluate the efficacy of AI-guided DS regimens using the GenAISâ?¢ system in improving glycemic control and metabolic health in patients with T2D. Methods: This randomized, parallel-group pilot trial included 160 patients with T2D, randomized into AI guided (n=80) and physician-guided (n=80) groups. The AI-guided group received personalized DS regimens based on genetic and metabolic profiles, while the physician-guided group received standard DS prescriptions. The study duration was 90 days, with the primary outcome being the change in HbA1c levels, and secondary outcomes including changes in fasting plasma glucose, HOMA-IR, insulin levels, BMI, waist circumference, and lipid profiles. Results: The AI-guided group showed a significant reduction in HbA1c levels (-0.3%; 95% CI: -0.5% to -0.1%; p < 0.01). Significant improvements were also observed in fasting plasma glucose, HOMA IR, insulin levels, BMI, waist circumference, and total cholesterol. Safety profiles were comparable between AI-guided and physician-guided groups. Conclusion: AI-guided DS regimens using GenAISâ?¢ significantly improved glycemic control and metabolic health in T2D patients, demonstrating the potential of AI-driven personalized medicine. Study 2: AI-Guided Dietary Supplements for Lowering LDL Cholesterol Objective: Assess the efficacy of AI-guided DS prescriptions using the GenAISâ?¢ system in reducing LDL cholesterol (LDL-C) levels compared to standard physician-guided prescriptions. Methods: This randomized, parallel-group pilot study involved 70 patients aged 40-75 years with LDL-C levels between 70-190 mg/dL. Participants were randomized to receive either AI-guided dietary supplement prescriptions or standard physician guided prescriptions for 90 days. The primary endpoint was the percent change in LDL-C levels, with secondary endpoints including changes in total cholesterol, HDL-C, triglycerides, and hsCRP. Results: The AI-guided group experienced a 25.3% reduction in LDL-C levels, significantly greater than the 15.2% reduction in the physician-guided group (p<0.01). Significant reductions in total cholesterol and triglycerides were also observed in the AI-guided group. Side effects were minimal and comparable between groups. Conclusion: AI-guided DS prescriptions using GenAISâ?¢ effectively reduced LDL-C and triglycerides more than traditional methods, highlighting AIâ??s potential in managing hypercholesterolemia through personalized supplementation. Implications for Clinical Practice: These studies underscore the transformative potential of AI in personalized healthcare, offering tailored interventions that significantly enhance therapeutic outcomes in chronic disease management. The integration of AI-driven personalized medicine Biography could revolutionize patient care, providing more effective, individualized treatment options for T2D and hypercholesterolemia.

Biography :

Evgeny Pokushalov is a Professor of Medicine who currently serves as the R&D Director at the Center of New Med ical Technologies (CNMT) in Novosibirsk, Russia, since 2020, while also holding the position of Medical Advisor to the Chairman of the Siberian Branch of the Russian Academy of Sciences since the same year. Additionally, since 2022, he has been associated with the Scientific Research Laboratory at Triangel Scientific in San Francisco, USA. From 1997 to 1999, Pokushalov studied at the Residency of Cardiology at the Tomsk Research Institute of Cardiology (Russia), where he got clinical training on cardiovascular disease. He got practical skills in electrophysiologic studies, both with a catheter and intraoperatively. Then he engaged in a postgraduate course in cardiosurgery for 3 years at the Tomsk Research Institute of Cardiology (Russia), where he got practical experience in conducting scientific clinical research. He has been an active member of various professional associations and colleges, including the Russian Society of Pacing and Electrophysiology, the European Society of Cardiology, the American Heart Associa t ion, and others, holding fellowships and memberships in prestigious organizations such as the European Society of Cardiology (FESC), the American College of Cardiology (FACC), the Heart Rhythm Society (FHRS), and the European Heart Rhythm Association (FEHRA).